Subsequent Therapies After mHSPC Progression on Darolutamide Offer Similar Survival
Investigators report survival by post-progression subsequent therapies after darolutamide for metastatic prostate cancer (mHSPC).
Source: renalandurologynews.com
Oliver Grimm News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Oliver Grimm. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Oliver Grimm Today - Breaking & Trending Today
:quality(70):focal(738x343:748x353)/cloudfront-eu-central-1.images.arcpublishing.com/irishtimes/E4DTWQ2ZHFGS3NDT6ZZ5LRQQLU.jpg)
German chancellor's Oscar Wilde misquote looks like carelessness – The Irish Times
Europe Letter: A citation by Olaf Scholz sounded more like something that would be shared on LinkedIn
Source: irishtimes.com
Adaptive Nivolumab Plus Ipilimumab Improves Outcomes in mRCC
Nivolumab plus ipilimumab for mRCC improves clinical outcomes compared with nivolumab alone.
Source: oncologynurseadvisor.com
Adaptive Nivolumab Plus Ipilimumab Improves Outcomes in mRCC
Nivolumab plus ipilimumab for mRCC improves clinical outcomes compared with nivolumab alone.
Source: renalandurologynews.com
Immune cell parameters linked to therapeutic efficacy in advanced renal cell carcinoma
SAN FRANCISCO — Certain immune cell-related parameters appeared associated with efficacy of immune checkpoint inhibitors among patients with advanced or metastatic clear cell renal cell carcinoma, according to study results.“These immune cell parameters may represent novel predictive biomarkers for the response to nivolumab and/or nivolumab plus ipilimumab therapy in clear cell [renal
Source: healio.com